J. Evans, T. Williams, B. Beattie, J-P. Michel and G. K. Wilcock (eds) Oxford Textbook of Geriatric Medicine (2nd Edition). Oxford University Press, Oxford, 2000, 1264 pp., hbk £175.00, ISBN 0 192 62830 5, pbk not available

Autor: Miriam Casey

Publikováno v: Ageing and Society. 21:357-368

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9b8336b4644282a2c55cda77e4c4784
https://doi.org/10.1017/s0144686x01008224

DIAGNOSIS AND MANAGEMENT OF DEMENTIA. A MANUALFOR MEMORY DISORDERS TEAMS. 1999. Edited by Gordon K. Wilcock, Romola S. Bucks and Kenneth Rockwood. Published by Oxford University Press Inc., New York. 402 pages C$86.95 approx

Autor: John R. Wherrett

Publikováno v: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 27:174-175

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78f4f6defe0b5efe628378a4eb1242cc
https://doi.org/10.1017/s0317167100052355

The management of alzheimer's disease. Edited by Gordon K. Wilcock. Wrightson Biomedical Publishing, Petersfield, 1993. No. of pages: 220

Autor: Robert Howard

Publikováno v: International Journal of Geriatric Psychiatry. 9:508-508

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1fd648c6cb4e8b8ece9fdf62ff8c4691
https://doi.org/10.1002/gps.930090612

Donepezil Enhances Frontal Functional Connectivity in Alzheimer's Disease: A Pilot Study

Autor: Ludovica Griffanti, Gordon K. Wilcock, Natalie Voets, Guendalina Bonifacio, Clare E. Mackay, Mark Jenkinson, Giovanna Zamboni

Publikováno v: Dementia and Geriatric Cognitive Disorders Extra, Vol 6, Iss 3, Pp 518-528 (2016)

Background: We have previously shown that increased resting-state functional magnetic resonance imaging (fMRI)-based functional connectivity (FC) within the frontal resting-state networks in Alzheimer's disease (AD) patients reflects residual, possib

Externí odkaz: https://doaj.org/article/fe5121a45fc642d795f9b7aae6faf2fa

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT

Autor: Simon Lovestone, Rosie Bradley, Rupert McShane, John T. O'Brien, Lynn Pank, Suzanne Reeves, G Livingston, Craig W. Ritchie, Gordon K. Wilcock, Chris Fox, Alistair Burns, Naji Tabet, Peter Bentham, Emma Harper, Robert Howard, Ramin Nilforooshan, Richard Gray, Wendy Noble, Linda Kelly, Olga Zubko, Clive Ballard

Publikováno v: Howard, R, Zubko, O, Gray, R, Bradley, R, Harper, E, Kelly, L, Pank, L, O’brien, J, Fox, C, Tabet, N, Livingston, G, Bentham, P, Mcshane, R, Burns, A, Ritchie, C, Reeves, S, Lovestone, S, Ballard, C, Noble, W, Wilcock, G & Nilforooshan, R 2020, ' Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT ', Efficacy and Mechanism Evaluation, vol. 7, no. 2 . https://doi.org/10.3310/eme07020
Efficacy and Mechanism Evaluation, Vol 7, Iss 2 (2020)
Howard, R, Zubko, O, Gray, R, Bradley, R, Harper, E, Kelly, L, Pank, L, O'Brien, J, Fox, C, Tabet, N, Livingston, G, Bentham, P, McShane, R, Burns, A, Ritchie, C, Reeves, S, Lovestone, S, Ballard, C, Noble, W, Wilcock, G & Nilforooshan, R 2020, ' Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT ', Efficacy and Mechanism Evaluation, vol. 7, no. 2, 7(2), pp. 1-45 . https://doi.org/10.3310/eme07020

Background Minocycline is an anti-inflammatory drug and protects against the toxic effects of β-amyloid in vitro and in animal models of Alzheimer’s disease. To the best of our knowledge, no randomised placebo-controlled clinical trials in patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c83ff20ca871c6a4d7c728d32a63c893
https://doi.org/10.3310/eme07020